title: [Serological surveillance on vaccine against hemorrhagic fever with renal syndrome].
abstract: OBJECTIVE
  To observe the serological and epidemiological efficacy of hemorrhagic fever renal syndrome (HFRS) vaccine in Zhejiang province.
  
  
  METHODS
  Immunofluorescent antibody assay and Mcro-CPE method were used to test specific IgG antibody and the titer of neutralizing antibody.
  
  
  RESULTS
  Two weeks after the injection of the third dose, the sero-conversion rates by both immunofluorescent antibody test (IgG) and neutralization test were 100.0% (67/67) (95% CI: 96.3 - 100.0) and 44.4% (8/18)(95% CI: 22.0 - 69.0) with geometric mean titers (GMTs) 72.1 and 4.6 respectively. The rates of seroconversion of immunofluorescent antibody by immunofluorescence antibody assay (IFA) were 28.6%, 83.3%, 75.0%, 53.1%, 22.6%, 10.0% and 55.0% before reinforcement, two weeks, one year, one year and a half years, two years, three years and five years after reinforcement. The rates of neutralizing antibody seroconversion by the Mcro-CPE method were found as 14.8%, 55.6%, 35.0%, 31.3%, 26.0%, 10.0% and 50.0% respectively. We found some antibody dependent immunization enhancement phenomenon among the inoculated population, but further observation was needed.
  
  
  CONCLUSIONS
  HFRS vaccine was immunologically effective and the duration of serous antibody last long.
authors.affiliation: Center for Disease Control and Prevention, Zhejiang Province, Hangzhou 310009, China.
authors.forename: Zhen-yu
authors.initials: ZY
authors.lastname: Gong
authors.forename: Jing-qing
authors.initials: JQ
authors.lastname: Weng
authors.forename: Zhi-ya
authors.initials: ZY
authors.lastname: Zhao
authors.forename: Yu-tu
authors.initials: YT
authors.lastname: Chen
authors.forename: A-gen
authors.initials: AG
authors.lastname: Zhu
authors.forename: Gui-ming
authors.initials: GM
authors.lastname: Fu
authors.forename: Chun-fu
authors.initials: CF
authors.lastname: Fang
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Zhu
authors.forename: En-fu
authors.initials: EF
authors.lastname: Chen
authors.forename: Chui-zhang
authors.initials: CZ
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Lin-hai
authors.initials: LH
authors.lastname: Lei
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D002681:China / Q000453:epidemiology; D005455:Fluorescent Antibody Technique; D018063:Hantaan virus / Q000276:immunology*; D006480:Hemorrhagic Fever with Renal Syndrome / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014765:Viral Vaccines